Skip to main content
Top
Published in: BMC Health Services Research 1/2012

Open Access 01-12-2012 | Research article

Nation-scale adoption of new medicines by doctors: an application of the Bass diffusion model

Authors: Adam G Dunn, Jeffrey Braithwaite, Blanca Gallego, Richard O Day, William Runciman, Enrico Coiera

Published in: BMC Health Services Research | Issue 1/2012

Login to get access

Abstract

Background

The adoption of new medicines is influenced by a complex set of social processes that have been widely examined in terms of individual prescribers’ information-seeking and decision-making behaviour. However, quantitative, population-wide analyses of how long it takes for new healthcare practices to become part of mainstream practice are rare.

Methods

We applied a Bass diffusion model to monthly prescription volumes of 103 often-prescribed drugs in Australia (monthly time series data totalling 803 million prescriptions between 1992 and 2010), to determine the distribution of adoption rates. Our aim was to test the utility of applying the Bass diffusion model to national-scale prescribing volumes.

Results

The Bass diffusion model was fitted to the adoption of a broad cross-section of drugs using national monthly prescription volumes from Australia (median R2 = 0.97, interquartile range 0.95 to 0.99). The median time to adoption was 8.2 years (IQR 4.9 to 12.1). The model distinguished two classes of prescribing patterns – those where adoption appeared to be driven mostly by external forces (19 drugs) and those driven mostly by social contagion (84 drugs). Those driven more prominently by internal forces were found to have shorter adoption times (p = 0.02 in a non-parametric analysis of variance by ranks).

Conclusion

The Bass diffusion model may be used to retrospectively represent the patterns of adoption exhibited in prescription volumes in Australia, and distinguishes between adoption driven primarily by external forces such as regulation, or internal forces such as social contagion. The eight-year delay between the introduction of a new medicine and the adoption of the prescribing practice suggests the presence of system inertia in Australian prescribing practices.
Appendix
Available only for authorised users
Literature
1.
go back to reference Berwick DM: Disseminating Innovations in Health Care. JAMA. 2003, 289 (15): 1969-1975. 10.1001/jama.289.15.1969.CrossRefPubMed Berwick DM: Disseminating Innovations in Health Care. JAMA. 2003, 289 (15): 1969-1975. 10.1001/jama.289.15.1969.CrossRefPubMed
2.
go back to reference Fuchs VR, Milstein A: The $640 Billion Question - Why Does Cost-Effective Care Diffuse So Slowly?. N Engl J Med. 2011, 364 (21): 1985-1987. 10.1056/NEJMp1104675.CrossRefPubMed Fuchs VR, Milstein A: The $640 Billion Question - Why Does Cost-Effective Care Diffuse So Slowly?. N Engl J Med. 2011, 364 (21): 1985-1987. 10.1056/NEJMp1104675.CrossRefPubMed
3.
go back to reference Kotchen TA: Why the Slow Diffusion of Treatment Guidelines Into Clinical Practice?. Arch Intern Med. 2007, 167 (22): 2394-2395. 10.1001/archinte.167.22.2394.CrossRefPubMed Kotchen TA: Why the Slow Diffusion of Treatment Guidelines Into Clinical Practice?. Arch Intern Med. 2007, 167 (22): 2394-2395. 10.1001/archinte.167.22.2394.CrossRefPubMed
4.
go back to reference Coleman J, Katz E, Menzel H: The Diffusion of an Innovation Among Physicians. Sociometry. 1957, 20 (4): 253-270. 10.2307/2785979.CrossRef Coleman J, Katz E, Menzel H: The Diffusion of an Innovation Among Physicians. Sociometry. 1957, 20 (4): 253-270. 10.2307/2785979.CrossRef
5.
go back to reference Coleman J, Katz E, Menzel H: Medical Innovation: A Diffusion Study. 1966, The Bobbs-Merrill Company, Indianapolis Coleman J, Katz E, Menzel H: Medical Innovation: A Diffusion Study. 1966, The Bobbs-Merrill Company, Indianapolis
6.
go back to reference Menzel H: Innovation, Integration, and Marginality: A Survey of Physicians. Am Sociol Rev. 1960, 25 (5): 704-713. 10.2307/2090143.CrossRef Menzel H: Innovation, Integration, and Marginality: A Survey of Physicians. Am Sociol Rev. 1960, 25 (5): 704-713. 10.2307/2090143.CrossRef
7.
go back to reference Winick C: The Diffusion of an Innovation Among Physicians in a Large City. Sociometry. 1961, 24 (4): 384-396. 10.2307/2785920.CrossRef Winick C: The Diffusion of an Innovation Among Physicians in a Large City. Sociometry. 1961, 24 (4): 384-396. 10.2307/2785920.CrossRef
8.
go back to reference Bastian H, Glasziou P, Chalmers I: Seventy-Five Trials and Eleven Systematic Reviews a Day: How Will We Ever Keep Up?. PLoS Med. 2010, 7 (9): e1000326-10.1371/journal.pmed.1000326.CrossRefPubMedPubMedCentral Bastian H, Glasziou P, Chalmers I: Seventy-Five Trials and Eleven Systematic Reviews a Day: How Will We Ever Keep Up?. PLoS Med. 2010, 7 (9): e1000326-10.1371/journal.pmed.1000326.CrossRefPubMedPubMedCentral
9.
go back to reference Fraser AG, Dunstan FD: On the impossibility of being expert. BMJ. 2010, 341. Fraser AG, Dunstan FD: On the impossibility of being expert. BMJ. 2010, 341.
10.
go back to reference Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL: How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010, 9: 203-214.PubMed Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL: How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010, 9: 203-214.PubMed
11.
go back to reference Brody H, Light DW: The Inverse Benefit Law: How Drug Marketing Undermines Patient Safety and Public Health. Am J Public Health. 2011, 101 (3): 399-404. 10.2105/AJPH.2010.199844.CrossRefPubMedPubMedCentral Brody H, Light DW: The Inverse Benefit Law: How Drug Marketing Undermines Patient Safety and Public Health. Am J Public Health. 2011, 101 (3): 399-404. 10.2105/AJPH.2010.199844.CrossRefPubMedPubMedCentral
12.
go back to reference DeAngelis CD, Fontanarosa PB: Impugning the Integrity of Medical Science: The Adverse Effects of Industry Influence. JAMA. 2008, 299 (15): 1833-1835. 10.1001/jama.299.15.1833.CrossRefPubMed DeAngelis CD, Fontanarosa PB: Impugning the Integrity of Medical Science: The Adverse Effects of Industry Influence. JAMA. 2008, 299 (15): 1833-1835. 10.1001/jama.299.15.1833.CrossRefPubMed
13.
go back to reference Lathyris DN, Patsopoulos NA, Salanti G, Ioannidis JPA: Industry sponsorship and selection of comparators in randomized clinical trials. Eur J Clin Invest. 2010, 40 (2): 172-182. 10.1111/j.1365-2362.2009.02240.x.CrossRefPubMed Lathyris DN, Patsopoulos NA, Salanti G, Ioannidis JPA: Industry sponsorship and selection of comparators in randomized clinical trials. Eur J Clin Invest. 2010, 40 (2): 172-182. 10.1111/j.1365-2362.2009.02240.x.CrossRefPubMed
14.
go back to reference Lenzer J: Many US medical associations and disease awareness groups depend heavily on funding by drug manufacturers. BMJ. 2011, 342: d2929-10.1136/bmj.d2929.CrossRefPubMed Lenzer J: Many US medical associations and disease awareness groups depend heavily on funding by drug manufacturers. BMJ. 2011, 342: d2929-10.1136/bmj.d2929.CrossRefPubMed
15.
go back to reference Lundh A, Barbateskovic M, Hróbjartsson A, Gøtzsche PC: Conflicts of Interest at Medical Journals: The Influence of Industry-Supported Randomised Trials on Journal Impact Factors and Revenue - Cohort Study. PLoS Med. 2010, 7 (10): e1000354-10.1371/journal.pmed.1000354.CrossRefPubMedPubMedCentral Lundh A, Barbateskovic M, Hróbjartsson A, Gøtzsche PC: Conflicts of Interest at Medical Journals: The Influence of Industry-Supported Randomised Trials on Journal Impact Factors and Revenue - Cohort Study. PLoS Med. 2010, 7 (10): e1000354-10.1371/journal.pmed.1000354.CrossRefPubMedPubMedCentral
16.
go back to reference Spurling GK, Mansfield PR, Montgomery BD, Lexchin J, Doust J, Othman N, Vitry AI: Information from Pharmaceutical Companies and the Quality, Quantity, and Cost of Physicians' Prescribing: A Systematic Review. PLoS Med. 2010, 7 (10): e1000352-10.1371/journal.pmed.1000352.CrossRefPubMedPubMedCentral Spurling GK, Mansfield PR, Montgomery BD, Lexchin J, Doust J, Othman N, Vitry AI: Information from Pharmaceutical Companies and the Quality, Quantity, and Cost of Physicians' Prescribing: A Systematic Review. PLoS Med. 2010, 7 (10): e1000352-10.1371/journal.pmed.1000352.CrossRefPubMedPubMedCentral
17.
go back to reference Doumit G, Gattellari M, Grimshaw J, O'Brien MA: Local opinion leaders: effects on professional practice and healthcare outcomes. Cochrane Database Syst Rev. 2007, 1: CD000125.PubMed Doumit G, Gattellari M, Grimshaw J, O'Brien MA: Local opinion leaders: effects on professional practice and healthcare outcomes. Cochrane Database Syst Rev. 2007, 1: CD000125.PubMed
18.
go back to reference Mintzes B: For and against: Direct to consumer advertising is medicalising normal human experience. BMJ. 2002, 324 (7342): 908-909. 10.1136/bmj.324.7342.908.CrossRefPubMedPubMedCentral Mintzes B: For and against: Direct to consumer advertising is medicalising normal human experience. BMJ. 2002, 324 (7342): 908-909. 10.1136/bmj.324.7342.908.CrossRefPubMedPubMedCentral
19.
go back to reference Mintzes B, Barer ML, Kravitz RL, Kazanjian AE, Bassett K, Lexchin J, Evans RG, Pan R, Marion SA: Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey. BMJ. 2002, 324 (7332): 278-279. 10.1136/bmj.324.7332.278.CrossRefPubMedPubMedCentral Mintzes B, Barer ML, Kravitz RL, Kazanjian AE, Bassett K, Lexchin J, Evans RG, Pan R, Marion SA: Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey. BMJ. 2002, 324 (7332): 278-279. 10.1136/bmj.324.7332.278.CrossRefPubMedPubMedCentral
20.
go back to reference Prosser H, Almond S, Walley T: Influences on GPs' decision to prescribe new drugs–the importance of who says what. Fam Pract. 2003, 20 (1): 61-68. 10.1093/fampra/20.1.61.CrossRefPubMed Prosser H, Almond S, Walley T: Influences on GPs' decision to prescribe new drugs–the importance of who says what. Fam Pract. 2003, 20 (1): 61-68. 10.1093/fampra/20.1.61.CrossRefPubMed
21.
go back to reference Prosser H, Walley T: New drug prescribing by hospital doctors: The nature and meaning of knowledge. Soc Sci Med. 2006, 62 (7): 1565-1578. 10.1016/j.socscimed.2005.08.035.CrossRefPubMed Prosser H, Walley T: New drug prescribing by hospital doctors: The nature and meaning of knowledge. Soc Sci Med. 2006, 62 (7): 1565-1578. 10.1016/j.socscimed.2005.08.035.CrossRefPubMed
22.
go back to reference Peay MY, Peay ER: Differences among practitioners in patterns of preference for information sources in the adoption of new drugs. Soc Sci Med. 1984, 18 (12): 1019-1025. 10.1016/0277-9536(84)90160-6.CrossRefPubMed Peay MY, Peay ER: Differences among practitioners in patterns of preference for information sources in the adoption of new drugs. Soc Sci Med. 1984, 18 (12): 1019-1025. 10.1016/0277-9536(84)90160-6.CrossRefPubMed
23.
go back to reference Peay MY, Peay ER: Patterns of preference for information sources in the adoption of new drugs by specialists. Soc Sci Med. 1990, 31 (4): 467-476. 10.1016/0277-9536(90)90042-Q.CrossRefPubMed Peay MY, Peay ER: Patterns of preference for information sources in the adoption of new drugs by specialists. Soc Sci Med. 1990, 31 (4): 467-476. 10.1016/0277-9536(90)90042-Q.CrossRefPubMed
24.
go back to reference Ratna N, Dray A, Perez P, Grafton R, Newth D, Kompas T: Diffusion and Social Networks: Revisiting Medical Innovation with Agents. Complex Decision Making. 2008, 30: 247-265. Ratna N, Dray A, Perez P, Grafton R, Newth D, Kompas T: Diffusion and Social Networks: Revisiting Medical Innovation with Agents. Complex Decision Making. 2008, 30: 247-265.
25.
go back to reference Dunn AG, Gallego B, Diffusion of competing innovations: The effects of network structure on the provision of healthcare. The Journal of Artificial Societies and Social Simulation. 2010, 13: 4.CrossRef Dunn AG, Gallego B, Diffusion of competing innovations: The effects of network structure on the provision of healthcare. The Journal of Artificial Societies and Social Simulation. 2010, 13: 4.CrossRef
26.
go back to reference Balas EA, Boren SA: Managing clinical knowledge for health care improvement. In: Yearbook of Medical Informatics 2000. Patient-Centered Systems. Edited by: Bemmel J, McCray AT. 2000, Schattauer Verlagsgesellschaft mbH, Stuttgart, Germany, 65 Balas EA, Boren SA: Managing clinical knowledge for health care improvement. In: Yearbook of Medical Informatics 2000. Patient-Centered Systems. Edited by: Bemmel J, McCray AT. 2000, Schattauer Verlagsgesellschaft mbH, Stuttgart, Germany, 65
27.
go back to reference Birkett DJ, McManus P: Modelling the market uptake of new drugs following listing for subsidy in Australia. A report from the Drug Utilisation Subcommittee of the Australian Pharmaceutical Benefits Advisory Committee. Br J Clin Pharmacol. 1995, 40 (4): 407-410. 10.1111/j.1365-2125.1995.tb04565.x.CrossRefPubMedPubMedCentral Birkett DJ, McManus P: Modelling the market uptake of new drugs following listing for subsidy in Australia. A report from the Drug Utilisation Subcommittee of the Australian Pharmaceutical Benefits Advisory Committee. Br J Clin Pharmacol. 1995, 40 (4): 407-410. 10.1111/j.1365-2125.1995.tb04565.x.CrossRefPubMedPubMedCentral
28.
go back to reference Brennan TA, Rothman DJ, Blank L, Blumenthal D, Chimonas SC, Cohen JJ, Goldman J, Kassirer JP, Kimball H, Naughton J, et al: Health Industry Practices That Create Conflicts of Interest: A Policy Proposal for Academic Medical Centers. JAMA. 2006, 295 (4): 429-433. 10.1001/jama.295.4.429.CrossRefPubMed Brennan TA, Rothman DJ, Blank L, Blumenthal D, Chimonas SC, Cohen JJ, Goldman J, Kassirer JP, Kimball H, Naughton J, et al: Health Industry Practices That Create Conflicts of Interest: A Policy Proposal for Academic Medical Centers. JAMA. 2006, 295 (4): 429-433. 10.1001/jama.295.4.429.CrossRefPubMed
29.
go back to reference Lamas GA, Pfeffer MA, Hamm P, Wertheimer J, Rouleau J-L, Braunwald E: Do the Results of Randomized Clinical Trials of Cardiovascular Drugs Influence Medical Practice?. N Engl J Med. 1992, 327 (4): 241-247. 10.1056/NEJM199207233270405.CrossRefPubMed Lamas GA, Pfeffer MA, Hamm P, Wertheimer J, Rouleau J-L, Braunwald E: Do the Results of Randomized Clinical Trials of Cardiovascular Drugs Influence Medical Practice?. N Engl J Med. 1992, 327 (4): 241-247. 10.1056/NEJM199207233270405.CrossRefPubMed
30.
go back to reference Stafford RS, Furberg CD, Finkelstein SN, Cockburn IM, Alehegn T, Ma J: Impact of Clinical Trial Results on National Trends in β-Blocker Prescribing, 1996-2002. JAMA. 2004, 291 (1): 54-62. 10.1001/jama.291.1.54.CrossRefPubMed Stafford RS, Furberg CD, Finkelstein SN, Cockburn IM, Alehegn T, Ma J: Impact of Clinical Trial Results on National Trends in β-Blocker Prescribing, 1996-2002. JAMA. 2004, 291 (1): 54-62. 10.1001/jama.291.1.54.CrossRefPubMed
31.
go back to reference Jackevicius CA, Tu JV, Ross JS, Ko DT, Carreon D, Krumholz HM: Use of Fibrates in the United States and Canada. JAMA. 2011, 305 (12): 1217-1224. 10.1001/jama.2011.353.CrossRefPubMedPubMedCentral Jackevicius CA, Tu JV, Ross JS, Ko DT, Carreon D, Krumholz HM: Use of Fibrates in the United States and Canada. JAMA. 2011, 305 (12): 1217-1224. 10.1001/jama.2011.353.CrossRefPubMedPubMedCentral
32.
go back to reference Rogers EM: Diffusion of Innovations. 2003, Free Press, New York, 5 Rogers EM: Diffusion of Innovations. 2003, Free Press, New York, 5
33.
go back to reference Mahajan V, Muller E: Innovation Diffusion and New Product Growth Models in Marketing. J Mark. 1979, 43 (4): 55-68. 10.2307/1250271.CrossRef Mahajan V, Muller E: Innovation Diffusion and New Product Growth Models in Marketing. J Mark. 1979, 43 (4): 55-68. 10.2307/1250271.CrossRef
34.
go back to reference Mahajan V, Muller E, Bass FM: New Product Diffusion Models in Marketing: A Review and Directions for Research. J Mark. 1990, 54 (1): 1-26. 10.2307/1252170.CrossRef Mahajan V, Muller E, Bass FM: New Product Diffusion Models in Marketing: A Review and Directions for Research. J Mark. 1990, 54 (1): 1-26. 10.2307/1252170.CrossRef
35.
go back to reference Meade N, Islam T: Modelling and forecasting the diffusion of innovation - A 25-year review. Int J Forecast. 2006, 22 (3): 519-545. 10.1016/j.ijforecast.2006.01.005.CrossRef Meade N, Islam T: Modelling and forecasting the diffusion of innovation - A 25-year review. Int J Forecast. 2006, 22 (3): 519-545. 10.1016/j.ijforecast.2006.01.005.CrossRef
36.
go back to reference Bass FM: A New Product Growth for Model Consumer Durables. Manag Sci. 1969, 15 (5): 215-227. 10.1287/mnsc.15.5.215.CrossRef Bass FM: A New Product Growth for Model Consumer Durables. Manag Sci. 1969, 15 (5): 215-227. 10.1287/mnsc.15.5.215.CrossRef
37.
go back to reference Bass FM: Comments on "A New Product Growth for Model Consumer Durables": The Bass Model. Manag Sci. 2004, 50 (12): 1833-1840. 10.1287/mnsc.1040.0300.CrossRef Bass FM: Comments on "A New Product Growth for Model Consumer Durables": The Bass Model. Manag Sci. 2004, 50 (12): 1833-1840. 10.1287/mnsc.1040.0300.CrossRef
38.
go back to reference Bemmaor AC, Lee J: The Impact of Heterogeneity and Ill-Conditioning on Diffusion Model Parameter Estimates. Mark Sci. 2002, 21 (2): 209-220. 10.1287/mksc.21.2.209.151.CrossRef Bemmaor AC, Lee J: The Impact of Heterogeneity and Ill-Conditioning on Diffusion Model Parameter Estimates. Mark Sci. 2002, 21 (2): 209-220. 10.1287/mksc.21.2.209.151.CrossRef
39.
go back to reference Norton JA, Bass FM: A Diffusion Theory Model of Adoption and Substitution for Successive Generations of High-Technology Products. Manag Sci. 1987, 33 (9): 1069-1086. 10.1287/mnsc.33.9.1069.CrossRef Norton JA, Bass FM: A Diffusion Theory Model of Adoption and Substitution for Successive Generations of High-Technology Products. Manag Sci. 1987, 33 (9): 1069-1086. 10.1287/mnsc.33.9.1069.CrossRef
40.
go back to reference van den Bulte C, Stremersch S: Social Contagion and Income Heterogeneity in New Product Diffusion: A Meta-Analytic Test. Mark Sci. 2004, 23 (4): 530-544. 10.1287/mksc.1040.0054.CrossRef van den Bulte C, Stremersch S: Social Contagion and Income Heterogeneity in New Product Diffusion: A Meta-Analytic Test. Mark Sci. 2004, 23 (4): 530-544. 10.1287/mksc.1040.0054.CrossRef
41.
go back to reference Talukdar D, Sudhir K, Ainslie A: Investigating New Product Diffusion across Products and Countries. Mark Sci. 2002, 21 (1): 97-114. 10.1287/mksc.21.1.97.161.CrossRef Talukdar D, Sudhir K, Ainslie A: Investigating New Product Diffusion across Products and Countries. Mark Sci. 2002, 21 (1): 97-114. 10.1287/mksc.21.1.97.161.CrossRef
43.
go back to reference Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M: Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004, 364 (9450): 2021-2029. 10.1016/S0140-6736(04)17514-4.CrossRefPubMed Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M: Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004, 364 (9450): 2021-2029. 10.1016/S0140-6736(04)17514-4.CrossRefPubMed
44.
go back to reference Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007, 356 (24): 2457-2471. 10.1056/NEJMoa072761.CrossRefPubMed Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007, 356 (24): 2457-2471. 10.1056/NEJMoa072761.CrossRefPubMed
45.
go back to reference Topol EJ: Failing the Public Health - Rofecoxib, Merck, and the FDA. N Engl J Med. 2004, 351 (17): 1707-1709. 10.1056/NEJMp048286.CrossRefPubMed Topol EJ: Failing the Public Health - Rofecoxib, Merck, and the FDA. N Engl J Med. 2004, 351 (17): 1707-1709. 10.1056/NEJMp048286.CrossRefPubMed
46.
go back to reference Cohen FJ: Entry order as a consideration for innovation strategies. Nat Rev Drug Discov. 2006, 5 (4): 285-294. 10.1038/nrd2009.CrossRefPubMed Cohen FJ: Entry order as a consideration for innovation strategies. Nat Rev Drug Discov. 2006, 5 (4): 285-294. 10.1038/nrd2009.CrossRefPubMed
47.
go back to reference DiMasi JA, Paquette C: The Economics of Follow-on Drug Research and Development: Trends in Entry Rates and the Timing of Development. PharmacoEconomics. 2004, 22: 1-14.CrossRefPubMed DiMasi JA, Paquette C: The Economics of Follow-on Drug Research and Development: Trends in Entry Rates and the Timing of Development. PharmacoEconomics. 2004, 22: 1-14.CrossRefPubMed
48.
go back to reference Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL: Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006, 367 (9524): 1747-1757. 10.1016/S0140-6736(06)68770-9.CrossRefPubMed Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL: Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006, 367 (9524): 1747-1757. 10.1016/S0140-6736(06)68770-9.CrossRefPubMed
49.
go back to reference Expert Panel on Detection E: Treatment of High Blood Cholesterol in A: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001, 285 (19): 2486-2497. 10.1001/jama.285.19.2486.CrossRef Expert Panel on Detection E: Treatment of High Blood Cholesterol in A: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001, 285 (19): 2486-2497. 10.1001/jama.285.19.2486.CrossRef
50.
go back to reference Wright M, Upritchard C, Lewis T: A Validation of the Bass New Product Diffusion Model in New Zealand. Mark Bull. 1997, 8: 15-29. Wright M, Upritchard C, Lewis T: A Validation of the Bass New Product Diffusion Model in New Zealand. Mark Bull. 1997, 8: 15-29.
51.
go back to reference Fruchter GE, Van den Bulte C: Why the Generalized Bass Model leads to odd optimal advertising policies. Int J Res Mark. , 28 (3): 218-230. Fruchter GE, Van den Bulte C: Why the Generalized Bass Model leads to odd optimal advertising policies. Int J Res Mark. , 28 (3): 218-230.
52.
go back to reference Jiang Z, Bass FM, Bass PI: Virtual Bass Model and the left-hand data-truncation bias in diffusion of innovation studies. Int J Res Mark. 2006, 23 (1): 93-106. 10.1016/j.ijresmar.2006.01.008.CrossRef Jiang Z, Bass FM, Bass PI: Virtual Bass Model and the left-hand data-truncation bias in diffusion of innovation studies. Int J Res Mark. 2006, 23 (1): 93-106. 10.1016/j.ijresmar.2006.01.008.CrossRef
53.
go back to reference van den Bulte C, Lilien GL: Bias and Systematic Change in the Parameter Estimates of Macro-Level Diffusion Models. Mark Sci. 1997, 16 (4): 338-353. 10.1287/mksc.16.4.338.CrossRef van den Bulte C, Lilien GL: Bias and Systematic Change in the Parameter Estimates of Macro-Level Diffusion Models. Mark Sci. 1997, 16 (4): 338-353. 10.1287/mksc.16.4.338.CrossRef
54.
go back to reference Iyengar R, Van den Bulte C, Valente TW: Opinion Leadership and Social Contagion in New Product Diffusion. Mark Sci. 2011, 30 (2): 195-212. 10.1287/mksc.1100.0566.CrossRef Iyengar R, Van den Bulte C, Valente TW: Opinion Leadership and Social Contagion in New Product Diffusion. Mark Sci. 2011, 30 (2): 195-212. 10.1287/mksc.1100.0566.CrossRef
55.
go back to reference Coiera E: Why system inertia makes health reform so difficult. BMJ. 2011, 342: d3693-10.1136/bmj.d3693.CrossRefPubMed Coiera E: Why system inertia makes health reform so difficult. BMJ. 2011, 342: d3693-10.1136/bmj.d3693.CrossRefPubMed
Metadata
Title
Nation-scale adoption of new medicines by doctors: an application of the Bass diffusion model
Authors
Adam G Dunn
Jeffrey Braithwaite
Blanca Gallego
Richard O Day
William Runciman
Enrico Coiera
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2012
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/1472-6963-12-248

Other articles of this Issue 1/2012

BMC Health Services Research 1/2012 Go to the issue